Pyridostigmine reduces QTc interval during recovery from maximal exercise in ischemic heart disease.
Following a randomized, cross-over, and double-blind design, 14 patients with coronary heart disease were submitted, to maximal cardiopulmonary exercise tests on a treadmill, 2 h after the oral administration of either placebo or pyridostigmine bromide (45 mg), a reversible cholinesterase inhibitor. One observer, who was blind to the experimental condition, measured RR and QT intervals over the 12 electrocardiographic leads in the first and third minute of active recovery from exercise. Paired t test was used to compare each variable measured in the same moment after placebo and pyridostigmine. Pyridostigmine reduced the QTc interval in the first minute of active recovery when compared to placebo (P=0.004). Two patients, whose heart rate recovery (1st minute) was below normal values (patient 1=4 bpm; patient 2=7 bpm; i.e. <12 bpm) presented with correction of this variable after pyridostigmine ingestion (patient 1=22 bpm; patient 2=36 bpm). Prospective trials should evaluate the impact of cholinergic stimulation with pyridostigmine on mortality.
Castro
Renata R T
RR
Serra
Salvador M
SM
Porphirio
Graciema
G
Mendes
Fernanda S N S
FS
Oliveira
Leonardo P J
LP
Nóbrega
Antonio C L
AC
D000284:Administration, Oral; D000368:Aged; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test; D017079:Exercise Tolerance / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects*; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000188:drug therapy*; D011729:Pyridostigmine Bromide / Q000008:administration & dosage / Q000627:therapeutic use*
D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide